DOCK3 and prostate carcinoma: Our study identified DOCK3 as a crucial player in PCa, particularly highlighting its ​novel dual role in promoting metastasis while concurrently modulating immune infiltration—a phenomenon not extensively reported in prostate cancer prior to this work.